|
Market Closed -
Xetra
09:05:56 18/08/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 22.10 EUR | +1.94% |
|
-0.36% | +5.04% |
| 18/08 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| 17/08 | FTSE 100 drifts lower as oil price pushes higher | AN |
| Market Cap | 7.57TCr 10TCr 8.85TCr 8.32TCr 14TCr 9,81400Cr 14TCr 98TCr 38TCr 4,90900Cr 38TCr 38TCr 16,35000Cr | P/E 2026 * |
14.3x | P/E 2027 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 9.49TCr 13TCr 11TCr 10TCr 18TCr 12,30500Cr 18TCr 1,22400Cr 48TCr 6,15400Cr 48TCr 47TCr 20,49900Cr | EV / Sales 2026 * |
2.79x | EV / Sales 2027 * | 2.59x |
| Free-Float |
92.75% | Yield 2026 * |
3.69% | Yield 2027 * | 3.97% |
Last Transcript: GSK plc
| 1 day | +1.94% | ||
| 1 week | -0.36% | ||
| Current month | -2.13% | ||
| 1 month | -2.17% | ||
| 3 months | +2.50% | ||
| 6 months | -14.93% | ||
| Current year | +5.04% |
| 1 week | 21.13 |  | 22.13 |
| 1 month | 21.13 | | 24.5 |
| Current year | 20.34 | | 26.14 |
| 1 year | 16.64 | | 26.14 |
| 3 years | 14.48 | | 26.14 |
| 5 years | 14.48 | | 27.23 |
| 10 years | 14.48 | | 27.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.94% | -0.36% | - | - | 10TCr | |
| +3.60% | +0.88% | +75.59% | +124.32% | 1,05500Cr | |
| +3.33% | +4.35% | +53.82% | +57.17% | 63TCr | |
| +3.43% | +3.53% | +25.34% | +72.45% | 44TCr | |
| +1.35% | -2.17% | +40.98% | +41.50% | 35TCr | |
| +1.75% | -0.24% | +25.28% | +40.46% | 29TCr | |
| +2.13% | -0.32% | +0.58% | +10.77% | 24TCr | |
| +1.41% | +2.65% | +45.34% | +62.43% | 23TCr | |
| +1.35% | -3.53% | -14.72% | -52.63% | 20TCr | |
| +3.25% | +5.65% | +21.57% | +89.04% | 17TCr | |
| Average | +2.35% | +0.10% | +30.42% | +49.50% | 40.14TCr | |
| Weighted average by Cap. | +2.76% | +0.23% | +43.70% | +68.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.39TCr 4.6TCr 3.97TCr 3.73TCr 6.38TCr 4,40300Cr 6.48TCr 44TCr 17TCr 2,20200Cr 17TCr 17TCr 7,33600Cr | 3.55TCr 4.81TCr 4.16TCr 3.91TCr 6.68TCr 4,61100Cr 6.78TCr 46TCr 18TCr 2,30600Cr 18TCr 18TCr 7,68100Cr |
| Net income | 543.57Cr 735.98Cr 635.66Cr 598.08Cr 1.02TCr 71TCr 1.04TCr 7.02TCr 2.75TCr 35TCr 2.76TCr 2.7TCr 1,17500Cr | 648.43Cr 877.95Cr 758.29Cr 713.45Cr 1.22TCr 84TCr 1.24TCr 8.37TCr 3.28TCr 42TCr 3.3TCr 3.22TCr 1,40100Cr |
| Net Debt | 1.92TCr 2.6TCr 2.25TCr 2.11TCr 3.61TCr 2,49100Cr 3.66TCr 25TCr 9.71TCr 1,24600Cr 9.76TCr 9.55TCr 4,14900Cr | 1.64TCr 2.22TCr 1.91TCr 1.8TCr 3.08TCr 2,12400Cr 3.12TCr 21TCr 8.28TCr 1,06200Cr 8.32TCr 8.14TCr 3,53800Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/26/18 | €22.10 | +1.94% | 33,137 |
| 17/26/17 | €21.68 | +2.12% | 39,025 |
| 14/26/14 | €21.23 | -2.12% | 27,565 |
| 13/26/13 | €21.69 | -0.78% | 16,510 |
| 12/26/12 | €21.86 | -1.44% | 41,205 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GS71 Stock
Select your edition
All financial news and data tailored to specific country editions
